GM101 Inhibits Cancer Survival and Resistance Pathways
We are seeking a pharma licensee or co-developer for our first-in-class biologic GM101 which is a Galectin-3 decoy. Galectin-3 is known to be active in multiple tumorigenic pathways. Suppressing multiple cell proliferation pathways provides our drug candidates and our pico-molar KD provide a clear competitive advantage compared to single action drugs.
Maryland residents are eligible to receive Biotechnology Investment Incentive Tax Credit (BIITC). BIITC provides an income tax credit equal to 50% of an eligible investment up to $250,000 per fiscal year. For more information, see